The DMPK team has extensive pharma and biotech experience delivering high-quality data, helping medicinal chemists design better compounds, and supporting better decisions throughout drug discovery. From the hit-to-lead through lead optimization, DMPK parameters help direct resources to the most promising chemical series and ensure the selection of the drug candidate.
Our comprehensive portfolio includes in vitro, and in vivo tests coupled with analytical techniques. We tailor flexible DMPK screening cascades specifically designed to boost medicinal chemistry programs, including the development of customized methods.
Absorption
- Chrom LogD
- LogD / LogP
- pKa
- Solubility (kinetic) (by LC-UV)
- Solubility (thermodynamic)
- Chemical stability
- Caco2
Distribution
- Plasma protein binding
- Blood plasma partitioning
- Tissue binding
Metabolism
- Microsomes
- Hepatocytes
- Long Term plated Hepatocytes
- Metabolite ID (microsomes/hepatocytes)
Drug Drug Interaction
- CYP inhibition (Available on Q1 2025)
- CYP3A Time Dependent Inhibition (Available on Q2 2025)
Excretion
- Determination of excretion route (rat PK -urine, faeces, bile)
In vivo pharmacokinetics
- Administration routes: intravenous, per os (PO), intra-peritoneal, subcutaneous
- Matrices: blood, plasma, tissues, bile, urine, and faeces
Preformulation
Developing an appropriate formulation is key to maximize in vivo exposure of therapeutics, the dedicated formulation team can perform the following studies:
- Design of a stable non-precipitating solution
- Early formulation development
- Advanced formulation for poorly soluble compounds
- Batch analysis and control
- Physicochemical properties of compounds
The data generated can help to better understand SAR as well as ADME and PK properties.
Our teams can work on small quantities to support early discovery projects.
